

We claim:

1. A combination for the treatment of Alzheimer's disease comprising an alpha-7-nicotinic agonist and a D1 receptor agonist, wherein the alpha-7-nicotinic agonist and the D1 receptor agonist together comprise a therapeutically effective amount of the alpha-7-nicotinic agonist and the D1 receptor agonist.
2. The combination of claim 1, wherein the combination is a single dosage form.
3. A method of treating Alzheimer's disease in a subject comprising administration to the subject a combination comprising an alpha-7-nicotinic agonist and a D1 receptor agonist, wherein the alpha-7-nicotinic agonist and the D1 receptor agonist together comprise a therapeutically effective amount of the alpha-7-nicotinic agonist and the D1 receptor agonist.
4. The method of treating a subject of claim 3, wherein the administration of each of the alpha-7-nicotinic agonist and the D1 receptor agonist occurs sequentially within about 24 hours.
5. The method of treating a subject of claim 3, wherein the administration of each of the alpha-7-nicotinic agonist and the D1 receptor agonist occurs sequentially within about 12 hours.
6. The method of treating a subject of claim 3, wherein the administration of each of the alpha-7-nicotinic agonist and the D1 receptor agonist occurs sequentially within about 6 hours.
7. The method of treating a subject of claim 3, wherein the administration of the alpha-7-nicotinic agonist and the D1 receptor agonist occurs sequentially within about 3 hours.
8. The method of treating a subject of claim 3, wherein the administration of each of the alpha-7-nicotinic agonist and the D1 receptor agonist occurs

sequentially within about 1 hour.

9. The method of treating a subject of claim 3, wherein the administration of each of the alpha-7-nicotinic agonist and the D1 receptor agonist occurs substantially concomitantly.

5 10. The method of treating a subject of claim 3, wherein the alpha-7-nicotinic agonist is administered daily to the subject and the D1 receptor agonist is administered on a cyclic basis to the subject.

11. The method of claim 10, wherein the cyclic basis comprises:

(a) administering the D1 receptor agonist daily for about 7, 14 or 21 days;

10 (b) not administering the D1 receptor agonist for about 7, 14 or 21 days;
and

(c) repeating steps (a) and (b) one or more times.